LUCENTIS®

$1,370.00

LUCENTIS® (Ranibizumab) 10 mg/ml is a targeted solution for treating vision loss caused by retinal diseases, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This anti-VEGF therapy helps restore and maintain visual acuity effectively.

Brand: LUCENTIS®
Manufacturer: Novartis
Active Substance: Ranibizumab
Strength: 10 mg/ml (2.3 mg per vial)
Pack Size: 1 vial (0.23 ml) + administration kit

Quantity Discount (%) Price
1 - 5 — $1,370.00
6 - 10 1.17 % $1,354.00
11 - 20 1.75 % $1,346.00
21+ 2.26 % $1,339.00
Sign In
Categories: , , Tag:
Lucentis Non Eng Front
Lucentis Non Eng Persp
Lucentis Non Eng Contents
Lucentis Non Eng Back

Additional information

LUCENTIS® 10 mg/ml, developed by Novartis, is an innovative intravitreal injection specifically designed to treat retinal conditions causing vision impairment. Its active ingredient, Ranibizumab, is a recombinant humanized monoclonal antibody fragment that targets and inhibits vascular endothelial growth factor A (VEGF-A), a key driver of abnormal blood vessel growth in the retina. By addressing the root cause of vision loss, LUCENTIS® reduces swelling, stabilizes vision, and, in many cases, improves visual acuity. The treatment is supplied in a single-use vial with a precise administration kit, ensuring safety and efficacy for clinical use.

Main Treatment Areas

LUCENTIS is indicated for the treatment of several vision-threatening retinal conditions:

  1. Wet Age-Related Macular Degeneration (AMD): Prevents the growth of abnormal blood vessels under the retina, stabilizing and improving vision.
  2. Diabetic Macular Edema (DME): Reduces fluid buildup in the macula caused by diabetic retinopathy, improving visual clarity.
  3. Retinal Vein Occlusion (RVO): Treats macular edema resulting from branch or central retinal vein occlusion.
  4. Myopic Choroidal Neovascularization (mCNV): Addresses vision loss caused by abnormal blood vessels due to severe nearsightedness.

These conditions are major contributors to progressive vision impairment, and LUCENTIS® offers a clinically proven solution for their management.

Key Benefits of LUCENTIS

  • Targeted Therapy: Inhibits VEGF-A to reduce abnormal blood vessel growth and leakage in the retina.
  • Improved Visual Acuity: Clinically proven to stabilize or significantly restore vision in patients with retinal conditions.
  • Rapid Action: Reduces retinal swelling and fluid accumulation effectively, improving vision quickly.
  • Long-Term Results: Helps maintain visual improvements over an extended treatment period.
  • Safe and Precise Delivery: Supplied with an administration kit for safe, intravitreal injections in a clinical setting.

LUCENTIS empowers ophthalmologists to provide an advanced solution for vision preservation and restoration.

Safety Information

LUCENTIS is for intravitreal injection only and must be administered by a trained ophthalmologist under sterile conditions. Patients should be monitored for increased intraocular pressure (IOP) and symptoms of endophthalmitis following treatment. Common side effects include mild eye irritation, redness, blurred vision, or floaters.

Rare but serious adverse effects may include retinal detachment, intraocular inflammation, or infections. Patients with hypersensitivity to ranibizumab or any of the formulation components should avoid this treatment. Pre-treatment evaluation, including thorough ocular examination, is essential to minimize risks. Store LUCENTIS® in a refrigerator at 2°C–8°C, and protect it from light until ready for use.

Pricing Information

To access specific pricing details and complete your purchase,  sign in to view detailed wholesale rates.

Related products